268 related articles for article (PubMed ID: 19036808)
1. DEK proto-oncogene expression interferes with the normal epithelial differentiation program.
Wise-Draper TM; Morreale RJ; Morris TA; Mintz-Cole RA; Hoskins EE; Balsitis SJ; Husseinzadeh N; Witte DP; Wikenheiser-Brokamp KA; Lambert PF; Wells SI
Am J Pathol; 2009 Jan; 174(1):71-81. PubMed ID: 19036808
[TBL] [Abstract][Full Text] [Related]
2. DEK promotes HPV-positive and -negative head and neck cancer cell proliferation.
Adams AK; Hallenbeck GE; Casper KA; Patil YJ; Wilson KM; Kimple RJ; Lambert PF; Witte DP; Xiao W; Gillison ML; Wikenheiser-Brokamp KA; Wise-Draper TM; Wells SI
Oncogene; 2015 Feb; 34(7):868-77. PubMed ID: 24608431
[TBL] [Abstract][Full Text] [Related]
3. Dek overexpression in murine epithelia increases overt esophageal squamous cell carcinoma incidence.
Matrka MC; Cimperman KA; Haas SR; Guasch G; Ehrman LA; Waclaw RR; Komurov K; Lane A; Wikenheiser-Brokamp KA; Wells SI
PLoS Genet; 2018 Mar; 14(3):e1007227. PubMed ID: 29538372
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of the cellular DEK protein promotes epithelial transformation in vitro and in vivo.
Wise-Draper TM; Mintz-Cole RA; Morris TA; Simpson DS; Wikenheiser-Brokamp KA; Currier MA; Cripe TP; Grosveld GC; Wells SI
Cancer Res; 2009 Mar; 69(5):1792-9. PubMed ID: 19223548
[TBL] [Abstract][Full Text] [Related]
5. Promotion of cell proliferation by the proto-oncogene DEK enhances oral squamous cell carcinogenesis through field cancerization.
Nakashima T; Tomita H; Hirata A; Ishida K; Hisamatsu K; Hatano Y; Kanayama T; Niwa A; Noguchi K; Kato K; Miyazaki T; Tanaka T; Shibata T; Hara A
Cancer Med; 2017 Oct; 6(10):2424-2439. PubMed ID: 28834425
[TBL] [Abstract][Full Text] [Related]
6. Apoptosis inhibition by the human DEK oncoprotein involves interference with p53 functions.
Wise-Draper TM; Allen HV; Jones EE; Habash KB; Matsuo H; Wells SI
Mol Cell Biol; 2006 Oct; 26(20):7506-19. PubMed ID: 16894028
[TBL] [Abstract][Full Text] [Related]
7. Role of the DEK oncogene in the development of squamous cell carcinoma.
Ishida K; Nakashima T; Shibata T; Hara A; Tomita H
Int J Clin Oncol; 2020 Sep; 25(9):1563-1569. PubMed ID: 32656741
[TBL] [Abstract][Full Text] [Related]
8. The human DEK proto-oncogene is a senescence inhibitor and an upregulated target of high-risk human papillomavirus E7.
Wise-Draper TM; Allen HV; Thobe MN; Jones EE; Habash KB; Münger K; Wells SI
J Virol; 2005 Nov; 79(22):14309-17. PubMed ID: 16254365
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of Epstein-Barr Virus Replication in Human Papillomavirus-Immortalized Keratinocytes.
Guidry JT; Myers JE; Bienkowska-Haba M; Songock WK; Ma X; Shi M; Nathan CO; Bodily JM; Sapp MJ; Scott RS
J Virol; 2019 Jan; 93(2):. PubMed ID: 30381489
[TBL] [Abstract][Full Text] [Related]
10. Squamous epithelial hyperplasia and carcinoma in mice transgenic for the human papillomavirus type 16 E7 oncogene.
Herber R; Liem A; Pitot H; Lambert PF
J Virol; 1996 Mar; 70(3):1873-81. PubMed ID: 8627712
[TBL] [Abstract][Full Text] [Related]
11. DEK proto-oncogene is highly expressed in astrocytic tumors and regulates glioblastoma cell proliferation and apoptosis.
Feng T; Liu Y; Li C; Li Z; Cai H
Tumour Biol; 2017 Jul; 39(7):1010428317716248. PubMed ID: 28670979
[TBL] [Abstract][Full Text] [Related]
12. IRAK1 is a novel DEK transcriptional target and is essential for head and neck cancer cell survival.
Adams AK; Bolanos LC; Dexheimer PJ; Karns RA; Aronow BJ; Komurov K; Jegga AG; Casper KA; Patil YJ; Wilson KM; Starczynowski DT; Wells SI
Oncotarget; 2015 Dec; 6(41):43395-407. PubMed ID: 26527316
[TBL] [Abstract][Full Text] [Related]
13. Melanoma proliferation and chemoresistance controlled by the DEK oncogene.
Khodadoust MS; Verhaegen M; Kappes F; Riveiro-Falkenbach E; Cigudosa JC; Kim DS; Chinnaiyan AM; Markovitz DM; Soengas MS
Cancer Res; 2009 Aug; 69(16):6405-13. PubMed ID: 19679545
[TBL] [Abstract][Full Text] [Related]
14. The DEK oncogene promotes cellular proliferation through paracrine Wnt signaling in Ron receptor-positive breast cancers.
Privette Vinnedge LM; Benight NM; Wagh PK; Pease NA; Nashu MA; Serrano-Lopez J; Adams AK; Cancelas JA; Waltz SE; Wells SI
Oncogene; 2015 Apr; 34(18):2325-36. PubMed ID: 24954505
[TBL] [Abstract][Full Text] [Related]
15. DEK over-expression promotes mitotic defects and micronucleus formation.
Matrka MC; Hennigan RF; Kappes F; DeLay ML; Lambert PF; Aronow BJ; Wells SI
Cell Cycle; 2015; 14(24):3939-53. PubMed ID: 25945971
[TBL] [Abstract][Full Text] [Related]
16. The DEK oncogene activates VEGF expression and promotes tumor angiogenesis and growth in HIF-1α-dependent and -independent manners.
Zhang Y; Liu J; Wang S; Luo X; Li Y; Lv Z; Zhu J; Lin J; Ding L; Ye Q
Oncotarget; 2016 Apr; 7(17):23740-56. PubMed ID: 26988756
[TBL] [Abstract][Full Text] [Related]
17. [Relationship between DEK oncogene expression and oral squamous cell carcinoma].
Wang X; Huang SH; Yu LQ; Liu J; Diao Y; Sun CF
Shanghai Kou Qiang Yi Xue; 2014 Feb; 23(1):75-9. PubMed ID: 24608617
[TBL] [Abstract][Full Text] [Related]
18. DEK-AFF2 fusion-associated papillary squamous cell carcinoma of the sinonasal tract: clinicopathologic characterization of seven cases with deceptively bland morphology.
Kuo YJ; Lewis JS; Zhai C; Chen YA; Chernock RD; Hsieh MS; Lan MY; Lee CK; Weinreb I; Hang JF
Mod Pathol; 2021 Oct; 34(10):1820-1830. PubMed ID: 34108636
[TBL] [Abstract][Full Text] [Related]
19. The Complexity of DEK Signaling in Cancer Progression.
Teng Y; Lang L; Jauregui CE
Curr Cancer Drug Targets; 2018; 18(3):256-265. PubMed ID: 28530531
[TBL] [Abstract][Full Text] [Related]
20. Silencing DEK downregulates cervical cancer tumorigenesis and metastasis via the DEK/p-Ser9-GSK-3β/p-Tyr216-GSK-3β/β-catenin axis.
Xu X; Zou L; Yao Q; Zhang Y; Gan L; Tang L
Oncol Rep; 2017 Aug; 38(2):1035-1042. PubMed ID: 28627610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
